�鶹��ýӰ��

Oncology/Hematology >

Chemotherapy

News, opinions and meeting coverage in oncology/hematology.

IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCR

Prognostic tool may predict who is likely to achieve a relatively long remission

Fludarabine, cyclophosphamide, and rituximab over a chronic lymphocytic leukemia (CLL) blood smear under light microscopy

FCR Still an Option in IGHV-Unmutated CLL?

Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit

ESMO over a photo of FIRA Barcelona, Spain

Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancer

Misses primary endpoints but has unexpected key benefit

The bottle and packaging of Imbruvica over an electrocardiogram

Ibrutinib's Cardiotoxicity Comes Into Focus

Study identifies new cardiac events linked to so-called targeted therapy

ASTRO over a photo of McCormick Place West, Chicago

Tx Deintensification Wins in Head and Neck Cancer, But ...

Only against another less-intensive approach in HPV-positive disease

WCLC over a photo of Gran Via, Fira de Barcelona

'Dirtier' Drugs Step Aside in RET-Positive NSCLC

Over two-thirds of patients respond to selective RET inhibitor

A woman receiving chemotherapy

Total Chemo Dose Still Matters in Breast Cancer

Worse survival with cumulative dose

ASCO over a photo of McCormick Place in Chicago.

Depth of Tumor Response a Better Survival Predictor

Could improve on RECIST as outcome measure in oncology

Computer rendering of breast cancer.

Omitting Chemo Feasible in First-Line HER2+ Breast Cancer?

De-escalation showed mixed results in metastatic disease

Three bottles of “Magic Mouthwash.”

'Magic Mouthwash' Little Help for Radiation-Induced Mucositis

Only statistical improvements in pain scores for head and neck cancer patients

Sheraton Grand hotel in Chicago with ACR-SOTA text overlaid.

Rheumatologist's Primer on Checkpoint Inhibitors

Specialist reviews the landscape of cancer drugs' autoimmune side effects

A photo of the Georgia World Conference Center with the acronym AACR overlaid.

PARP Inhibitor Maintenance for Pancreatic Cancer

Study takes cue from new treatment paradigm in BRCA-mutant ovarian cancer

A photo of the Georgia World Conference Center with the acronym AACR overlaid

Reversing Melanoma Resistance to Immunotherapy

HDAC inhibitor/anti-PD-1 combo active after initial anti-PD-1 failure

A photo of the Georgia World Conference Center with the acronym AACR overlaid.

MET Inhibitor Rescues Some Targeted Tx Failures in NSCLC

Savolitinib promising in patients with MET-based resistance to EGFR inhibition

An elderly dying man receives medication from a small cup.

Aggressive Tx Remains Common for Adults, Children Near Death

Many patients continue with treatments they probably don't need

Early Data Send Strong Signal in Advanced Gyn Cancers

Clinical benefit rate tops 90% in pair of single-center studies

When PARP Inhibitors Fail in Ovarian Cancer

Study identifies subgroup for whom another go could be worthwhile

Avelumab Combo Falls Short in Advanced Ovarian Ca

But showed promise in PD-L1-positive group

Zytiga May Up Mortality Risk in Prostate Cancer Patients With CVD

Increased hospitalizations seen among all abiraterone-treated patients

Genetic Profiling Disappoints for CUP Survival

But testing in cancer of unknown primary site did help with prognosis

Surgery/HIPEC Safer Than Other High-Risk Cancer Procedures

Lower infection, 30-day mortality rates than with Whipple, esophagectomy

Cancer Treatment and Arthritis: A Growing Complaint

Will checkpoint inhibitor-related arthritis outstrip RA in frequency?

Higher Risk of Shingles Seen in Patients With Certain Cancers

Vaccine development may help with prevention of herpes zoster in this population

Visual Guide to AVERT's VTE Prevention in Cancer

Apixaban effective against important chemotherapy side effect

Low-Dose Tamoxifen Feasible Option in Breast Cancer

Women appear to prevent recurrence in early stage cancers with 5 mg dosing

Cetuximab Fails Twice vs Cisplatin for HPV-Related Oral Ca

Cetuximab resulted in more patient deaths across U.S., German studies

Study: Paclitaxel Best for HIV-Related Kaposi's Sarcoma

Other chemotherapies fall behind in resource-limited setting

Is Drug Vial Optimization in Peril? Pharmacy Practice News

Also, how to advance your leadership skills

Ditching Chemo Appears Viable in Frontline Follicular Lymphoma

PFS 'nearly identical' at 3 years with novel immunomodulatory combination

PFS Rises in Ovarian Ca with Repeat Bevacizumab

Magnitude of benefit similar to first-line therapy

Many with Metastatic Kidney Cancer Can Skip Surgery

Overall survival with single-agent sunitinib better than with resection

Hot Chemo Fails in Rare Cancer

HIPEC and surgery equals surgery alone in peritoneal carcinomatosis

Rare Childhood Cancer Gets First Tx Advance in 30 Years

But impact unclear for U.S. rhabdomyosarcoma patients

Keytruda Alone Bests Chemo in Advanced NSCLC

Monotherapy boosts survival in patients with low PD-L1, no EGFR or ALK alterations

Chemo-Induced Neuropathy Common after Childhood Cancer

Neurotoxicity more prevalent in children treated with cisplatin

Make the Diagnosis: What’s to Blame for his Rash and Paresthesia?

Case Findings: A 52-year-old man who was undergoing chemotherapy for leukemia went to the ED 5 days after receiving cytarabine. He complained of a rapid onset of erythematous lesions on his palms and soles accompanied by tingling and burning sensations. Can you diagnose the patient?

Vince DeVita’s Oncology Opus

Medicine and music share center stage in storied career

'A Very Dangerous Interpretation': What We Heard This Week

Quotable quotes from MedPage Today's sources

MSK Cancer Alliance: Mainly About Medicine

Bi-directional relationship strengthens regional cancer care

'Jurassic' Clinical Trial Yields Prostate Cancer Guidance

Negative trial informs new studies of adjuvant therapy

4